Shadrach Chinecherem Eze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shadrach Chinecherem Eze has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Wande Michael Oluyemi
Department of Pharmaceutical and Medicinal Chemistry, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria
8 shared publications - Adeniyi Thompson Adewumi
Department of Life and Consumer Sciences, Calabash Building, Room 02-026, University of South Africa, Johannesburg, South Africa
6 shared publications - Salerwe Mosebi
Department of Life and Consumer Sciences, Calabash Building, Room 02-026, University of South Africa, Johannesburg, South Africa
6 shared publications - Evaristus Chinonso Odoh
University of Nigeria, Nigeria
3 shared publications - Augustine Chidi Madueke
Drug Discovery Unit, Department of Biochemistry, University of Nigeria, Nsukka 410001, Nigeria
2 shared publications Catherine C. Eleje
Federal Teaching Hospital Lokoja Nigeria
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by MDPI AG in Preprints.org
Towards New Antidiabetic Development: Molecular Interactions Unfold Potential Agonistic Mechanisms of Naturally Occurring Terpenoids Against Structural Landscape of Glucagon-like Peptide-1 Receptor
Glucagon-like peptide-1 receptor (GLP-1R) is a focal target in antidiabetic drug discovery. Synthetic non-peptide compounds are routinely employed to investigate GLP-1R, however, scaffolds from natural products will offer us unique structural diversity to design more potent compounds. We investigated the potential of some natural compounds as agonists of GLP-1R. First, we carried out a virtual screening of 244 compounds, from 19 medicinal plants used in antidiabetic traditional medicine, against GLP-1R. We used molecular dynamics simulations, for 200ns, to further investigate the lead five compounds. Binding Free Energies (BFE), Root Mean Square Deviation (RMSD) and other parameters were employed to understand these interactions. Our results showed that lupeol (-57.23) had good BFE (kcal/mol) compared to danuglipron (-56.47), thus demonstrating more robust interactions with GLP-1R. The pocket-buried residues, CYS191 and GLN186, showed strong hydrogen bonds while the critical residue, TRP4, showed strong van der Waals interactions to stabilize the ligands. Moreover, the average RMSD (Å) of lupeol-bound GLP-1R (3.45) are comparable to danuglipron-bound GLP-1R (3.33), indicating good stability in the pocket. This potentially situates lupeol as GLP-1R agonist similar to danuglipron, and thus opens up the opportunity for more further experimental work, to validate its agonist properties on GLP1R.
- 3 November 2026
- Published by MDPI AG in Preprints.org
Open AccessTowards New Antidiabetic Development: Molecular Interactions Unfold Potential Agonistic Mechanisms of Naturally Occurring Terpenoids Against Structural Landscape of Glucagon-like Peptide-1 Receptor
Glucagon-like peptide-1 receptor (GLP-1R) is a focal target in antidiabetic drug discovery. Synthetic non-peptide compounds are routinely employed to investigate GLP-1R, however, scaffolds from natural products will offer us unique structural diversity to design more potent compounds. We investigated the potential of some natural compounds as agonists of GLP-1R. First, we carried out a virtual screening of 244 compounds, from 19 medicinal plants used in antidiabetic traditional medicine, against GLP-1R. We used molecular dynamics simulations, for 200ns, to further investigate the lead five compounds. Binding Free Energies (BFE), Root Mean Square Deviation (RMSD) and other parameters were employed to understand these interactions. Our results showed that lupeol (-57.23) had good BFE (kcal/mol) compared to danuglipron (-56.47), thus demonstrating more robust interactions with GLP-1R. The pocket-buried residues, CYS191 and GLN186, showed strong hydrogen bonds while the critical residue, TRP4, showed strong van der Waals interactions to stabilize the ligands. Moreover, the average RMSD (Å) of lupeol-bound GLP-1R (3.45) are comparable to danuglipron-bound GLP-1R (3.33), indicating good stability in the pocket. This potentially situates lupeol as GLP-1R agonist similar to danuglipron, and thus opens up the opportunity for more further experimental work, to validate its agonist properties on GLP1R.
- Open Access
- 27 October 2026
- Published by MDPI AG in Preprints.org
Beyond Arbitrary Selection: A Multi‐Target Virtual Screening Framework to Reveal Antimalarial Potential of Natural Products Against Plasmodium falciparum PKG and MAP
Molecular docking (MD) have improved our understanding of how bioactive natural products (NPs) interact with Plasmodium Falciparum targets, to elicit their pharmacological actions. MD is done by selecting a few molecular targets, and placing them in the active site, to discover the most affinity-favoured compounds. However, the number of proteins selected for such MD influence ones assertion about the possible binding targets of the NPs under study. Using few protein targets limits docking score comparisons, which is the basis for the identification of potential multi-target NPs for antimalaria therapy. In addition, docking without molecular dynamics simulations (MDS), limits insights about the flexibility of target-ligand interactions in real biological systems. We had proposed multi-target virtual screening (with number of proteins => 10) as a prerequisite in studies evaluating potential binding targets of NPs. This, followed by distribution plots and or heatmap plots, can help prioritize targets and ligands for further MDS and then experimental validation. Using this strategy, we docked 1000+ NPs against 18 high-priority Plasmodium falciparum targets to select high-affinity binders, including compound C761 with multi-target potential against PfPKG and PfMAP. Though binding free energy from MDS did not correlate with docking scores, other results like RMSD, ROG and PCA suggest favourable conformational changes that can be explored for possible dual inhibition of PfPKG and PfAAP by C761. Our study provides a baseline framework to help researchers design better virtual screening workflows in elucidating molecular targets of natural products against Plasmodium falciparum.
- 27 October 2026
- Published by MDPI AG in Preprints.org
Open AccessBeyond Arbitrary Selection: A Multi‐Target Virtual Screening Framework to Reveal Antimalarial Potential of Natural Products Against Plasmodium falciparum PKG and MAP
Molecular docking (MD) have improved our understanding of how bioactive natural products (NPs) interact with Plasmodium Falciparum targets, to elicit their pharmacological actions. MD is done by selecting a few molecular targets, and placing them in the active site, to discover the most affinity-favoured compounds. However, the number of proteins selected for such MD influence ones assertion about the possible binding targets of the NPs under study. Using few protein targets limits docking score comparisons, which is the basis for the identification of potential multi-target NPs for antimalaria therapy. In addition, docking without molecular dynamics simulations (MDS), limits insights about the flexibility of target-ligand interactions in real biological systems. We had proposed multi-target virtual screening (with number of proteins => 10) as a prerequisite in studies evaluating potential binding targets of NPs. This, followed by distribution plots and or heatmap plots, can help prioritize targets and ligands for further MDS and then experimental validation. Using this strategy, we docked 1000+ NPs against 18 high-priority Plasmodium falciparum targets to select high-affinity binders, including compound C761 with multi-target potential against PfPKG and PfMAP. Though binding free energy from MDS did not correlate with docking scores, other results like RMSD, ROG and PCA suggest favourable conformational changes that can be explored for possible dual inhibition of PfPKG and PfAAP by C761. Our study provides a baseline framework to help researchers design better virtual screening workflows in elucidating molecular targets of natural products against Plasmodium falciparum.
- Open Access
- 17 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2366
Computational Analysis of the Homologous Mouse Double RINGs Interface for Targeted Anticancer Drug Design
Background/Objectives: The new yearly 1.1 million cancer cases and considerably increasing mortality, after decades of decline, require urgent and effective therapy. Targeted anticancer therapy is an attractive strategy for treating cancer by targeting critical receptors. The MDM2-MDMX RING heterodimer downregulates the p53 tumor suppressor pathway, making its disruption a primary therapeutic strategy in oncology. This study evaluates a series of novel inhibitors against the MDM2-MDMX RING interface to identify potent candidates that overcome the binding affinity and structural stability limitations of current small-molecule options like HLI373. Methods: Comprehensive computational simulations and MM/PBSA energy calculations were performed on five inhibitor complexes: Hinokiflavone, MMRi62, MMRi64, MMRi71, and HLI373. Structural stability, flexibility, and compactness were rigorously analyzed across a 200 ns molecular dynamics simulation trajectory using Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) metrics alongside Principal Component Analysis. Results: Among the evaluated MDM2-MDMX dual inhibitors, MMRi62 demonstrated the strongest binding affinity with a ΔGbind of −26.42 kcal/mol, outperforming reference HLI373 (−14.09 kcal/mol), Hinokiflavone (−22.69 kcal/mol), and MMRi64 (−16.73 kcal/mol). Structurally, MMRi64-bound complexes exhibited the highest stability, achieving the lowest RMSD of 2.28 Å and RMSF of 1.30 Å. Conversely, HLI373-bound complexes displayed pronounced structural fluctuations, yielding a high RMSD of 5.11 Å. Conclusions: These inhibitors present highly promising alternatives to HLI373 for targeting the MDM2-MDMX RING interface. MMRi62 and Hinokiflavone, in particular, stand out as highly potent dual-inhibitor leads for future targeted anticancer therapy development.
- 17 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2366
Open AccessComputational Analysis of the Homologous Mouse Double RINGs Interface for Targeted Anticancer Drug Design
Background/Objectives: The new yearly 1.1 million cancer cases and considerably increasing mortality, after decades of decline, require urgent and effective therapy. Targeted anticancer therapy is an attractive strategy for treating cancer by targeting critical receptors. The MDM2-MDMX RING heterodimer downregulates the p53 tumor suppressor pathway, making its disruption a primary therapeutic strategy in oncology. This study evaluates a series of novel inhibitors against the MDM2-MDMX RING interface to identify potent candidates that overcome the binding affinity and structural stability limitations of current small-molecule options like HLI373. Methods: Comprehensive computational simulations and MM/PBSA energy calculations were performed on five inhibitor complexes: Hinokiflavone, MMRi62, MMRi64, MMRi71, and HLI373. Structural stability, flexibility, and compactness were rigorously analyzed across a 200 ns molecular dynamics simulation trajectory using Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) metrics alongside Principal Component Analysis. Results: Among the evaluated MDM2-MDMX dual inhibitors, MMRi62 demonstrated the strongest binding affinity with a ΔGbind of −26.42 kcal/mol, outperforming reference HLI373 (−14.09 kcal/mol), Hinokiflavone (−22.69 kcal/mol), and MMRi64 (−16.73 kcal/mol). Structurally, MMRi64-bound complexes exhibited the highest stability, achieving the lowest RMSD of 2.28 Å and RMSF of 1.30 Å. Conversely, HLI373-bound complexes displayed pronounced structural fluctuations, yielding a high RMSD of 5.11 Å. Conclusions: These inhibitors present highly promising alternatives to HLI373 for targeting the MDM2-MDMX RING interface. MMRi62 and Hinokiflavone, in particular, stand out as highly potent dual-inhibitor leads for future targeted anticancer therapy development.
- Open Access
- 23 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Optimizing Affinity and Pharmacokinetics of a Cysteine-sulfoxide Derivative as Potential Inhibitor of BACE-1 using Fragment Growing and Molecular Dynamics
Alliin (S-(2-propenyl)-L-cysteine sulfoxide) was initially identified as a potential inhibitor of BACE-1, with the ability to chelate the catalytic dyad, but with very poor pharmacokinetics. We aimed to optimize these pharmacokinetic parameters, with a possible gain in affinity by growing the ligand towards the sub-pocket of the active site under the flaps. We employed fragment growing, implemented in the ligand designer module of Schrodinger, to extend 2-propenyl-alliin (a derivative of alliin) from both ends, with the multiparameter optimization (MPO) score as a guide. Select hits were further validated using molecular dynamics simulations for 500ns in explicit water. Ligands C37, C47, and C57 showed MPO scores above 0.9 with great improvements in LogP ranging from 1.129 to 2.147 and MW from 358g/mol to 384g/mol compared to -0.421 and 225.35g/mol in 2-propenyl-alliin, respectively. All the derivatives maintained an iron-clad charged contacts with the aspartic dyad throughout the simulation; while C47 and C57 made π-π interactions with Phe112 under the flap, using their pyridine side chains. Global root mean square deviations (RMSD), ligand RMSD, and root mean square fluctuations showed very stable ligand-BACE-1 complexes. Binding free energies (BFE; kcal/mol), computed using the MMGBSA, were two-fold higher (in C47, -52.29 ± 5.56 kcal/mol and C57, -59.40 ± 4.66) than that of the verubecestat (-26.78± 3.91), or alliin (−33.82 ± 4.25) in the previously reported work. However, the ligand-bound BACE-1 maintained an open conformation (distance D0>13.0Å). We have utilized fragment growing and molecular dynamics to provide derivatives of cysteinyl sulfoxides with improved pharmacokinetics, hydrophobic contact with Phe112, and improved BFE, while maintaining interactions with the catalytic dyad of BACE-1.
- 23 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessOptimizing Affinity and Pharmacokinetics of a Cysteine-sulfoxide Derivative as Potential Inhibitor of BACE-1 using Fragment Growing and Molecular Dynamics
Alliin (S-(2-propenyl)-L-cysteine sulfoxide) was initially identified as a potential inhibitor of BACE-1, with the ability to chelate the catalytic dyad, but with very poor pharmacokinetics. We aimed to optimize these pharmacokinetic parameters, with a possible gain in affinity by growing the ligand towards the sub-pocket of the active site under the flaps. We employed fragment growing, implemented in the ligand designer module of Schrodinger, to extend 2-propenyl-alliin (a derivative of alliin) from both ends, with the multiparameter optimization (MPO) score as a guide. Select hits were further validated using molecular dynamics simulations for 500ns in explicit water. Ligands C37, C47, and C57 showed MPO scores above 0.9 with great improvements in LogP ranging from 1.129 to 2.147 and MW from 358g/mol to 384g/mol compared to -0.421 and 225.35g/mol in 2-propenyl-alliin, respectively. All the derivatives maintained an iron-clad charged contacts with the aspartic dyad throughout the simulation; while C47 and C57 made π-π interactions with Phe112 under the flap, using their pyridine side chains. Global root mean square deviations (RMSD), ligand RMSD, and root mean square fluctuations showed very stable ligand-BACE-1 complexes. Binding free energies (BFE; kcal/mol), computed using the MMGBSA, were two-fold higher (in C47, -52.29 ± 5.56 kcal/mol and C57, -59.40 ± 4.66) than that of the verubecestat (-26.78± 3.91), or alliin (−33.82 ± 4.25) in the previously reported work. However, the ligand-bound BACE-1 maintained an open conformation (distance D0>13.0Å). We have utilized fragment growing and molecular dynamics to provide derivatives of cysteinyl sulfoxides with improved pharmacokinetics, hydrophobic contact with Phe112, and improved BFE, while maintaining interactions with the catalytic dyad of BACE-1.
- Open Access
- 25 August 2026
- Published by MDPI AG in Preprints.org
Computational Analysis of the Homologous Mouse Double RINGs Interface for Targeted Anticancer Drug Design
The new yearly 1.1 million cancer surges and considerably increasing mortality, post-decades of decline, require urgent and effective therapy. Targeted anticancer therapy is an attractive strategy for treating cancer by targeting critical receptors. Homologous Mouse Double-Minute RINGs (MDM2-MDMX RING) negatively regulate the p53 tumour-suppressing role by promoting proteasomal degradation. Interventively, Hinok., MMRi62, MMRi64, and MMRi71 exert a therapeutic downregulation against MDM2-MDMX RING heterodimer by activating p53’s apoptotic arm, but their binding mechanisms remain poorly understood due to the RING domain’s high structural flexibility and lack of co-crystal structures. This study reveals the underlying dynamic conformational stability and flexibility of the MDM2G443T-MDMX interface, and the potential mechanistic inhibitor binding using the all-atom MD simulations. The MMRi64-bound and Hinok-bound systems exhibited the lowest RMSD values (2.28 Å and 2.34 Å, respectively), indicating significant protein stabilization. MMRi71-bound (1.03 Å) and MMRi64-bound (1.30 Å) complexes displayed the lowest mean RMSF values, demonstrating that these ligands lock the protein into a rigid conformation. Conversely, the MMRi62-bound system showed the highest average RMSD and the highest RMSF (1.74 Å), identifying it as the most flexible complex. The ligand-bound MDM2G443T-MDMX complex underwent notable secondary structure transitions. MMGB/PBSA calculations revealed favorable binding free energies (-22.69, -26.42, and -20.30 kcal/mol) for the key interactions. Arg444, Pro445, Lys473, and Pro476 provided the highest binding free energy contributions to the RING domains. Over the 200 ns simulation, Hinok demonstrated dual interactions with both MDM2G443T-MDMX RING domains, highlighting a potential dual-inhibition mechanism, whereas MMRis interacted selectively with MDM2.
- 25 August 2026
- Published by MDPI AG in Preprints.org
Open AccessComputational Analysis of the Homologous Mouse Double RINGs Interface for Targeted Anticancer Drug Design
The new yearly 1.1 million cancer surges and considerably increasing mortality, post-decades of decline, require urgent and effective therapy. Targeted anticancer therapy is an attractive strategy for treating cancer by targeting critical receptors. Homologous Mouse Double-Minute RINGs (MDM2-MDMX RING) negatively regulate the p53 tumour-suppressing role by promoting proteasomal degradation. Interventively, Hinok., MMRi62, MMRi64, and MMRi71 exert a therapeutic downregulation against MDM2-MDMX RING heterodimer by activating p53’s apoptotic arm, but their binding mechanisms remain poorly understood due to the RING domain’s high structural flexibility and lack of co-crystal structures. This study reveals the underlying dynamic conformational stability and flexibility of the MDM2G443T-MDMX interface, and the potential mechanistic inhibitor binding using the all-atom MD simulations. The MMRi64-bound and Hinok-bound systems exhibited the lowest RMSD values (2.28 Å and 2.34 Å, respectively), indicating significant protein stabilization. MMRi71-bound (1.03 Å) and MMRi64-bound (1.30 Å) complexes displayed the lowest mean RMSF values, demonstrating that these ligands lock the protein into a rigid conformation. Conversely, the MMRi62-bound system showed the highest average RMSD and the highest RMSF (1.74 Å), identifying it as the most flexible complex. The ligand-bound MDM2G443T-MDMX complex underwent notable secondary structure transitions. MMGB/PBSA calculations revealed favorable binding free energies (-22.69, -26.42, and -20.30 kcal/mol) for the key interactions. Arg444, Pro445, Lys473, and Pro476 provided the highest binding free energy contributions to the RING domains. Over the 200 ns simulation, Hinok demonstrated dual interactions with both MDM2G443T-MDMX RING domains, highlighting a potential dual-inhibition mechanism, whereas MMRis interacted selectively with MDM2.
- Open Access
- 5 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Machine learning-guided rapid virtual screening and molecular dynamics validation of compounds against select Plasmodium falciparum targets
- 5 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessMachine learning-guided rapid virtual screening and molecular dynamics validation of compounds against select Plasmodium falciparum targets
- Open Access
- 2 June 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (3) , 47
Revisiting BACE-1: How Machine Learning and Molecular Dynamics Unveiled Potential Anti-Alzheimer’s Activity of a Cysteinyl Sulfoxide Derivative
Beta Secretase (BACE1) is a well-validated target for Alzheimer’s therapies, but there has been attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and dynamics were used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307 ± 0.109 Å) compared to Verubecestat (1.602 ± 0.159 Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (−33.820 ± 4.254) had comparatively lower energy than Verubecestat (−21.090 ± 6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 and Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrates the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.
- 2 June 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (3) , 47
Open AccessRevisiting BACE-1: How Machine Learning and Molecular Dynamics Unveiled Potential Anti-Alzheimer’s Activity of a Cysteinyl Sulfoxide Derivative
Beta Secretase (BACE1) is a well-validated target for Alzheimer’s therapies, but there has been attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and dynamics were used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307 ± 0.109 Å) compared to Verubecestat (1.602 ± 0.159 Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (−33.820 ± 4.254) had comparatively lower energy than Verubecestat (−21.090 ± 6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 and Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrates the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.
- Open Access
- 29 March 2026
- Published by University of Nigeria in Advanced Pharmaceutical and Biomedical Letters
- Vol. 2026 (1) , 78-91
Dusts and De-dusting of Natural Products Datasets: A Critical Review of the Challenges
Machine learning and artificial intelligence have become an established part of natural-products (NP) drug discovery. From bioactivity, hit-identification and lead optimization to toxicity and pharmacokinetic profiling, predictive models have sustained increased momentum. While many review works have focused on the models underlying predictions in NP drug discovery, a detailed understanding of how the quality of the data impacts the predictive process is still lacking. In this narrative review, we undertake the task of unravelling the shortcomings of the current datasets we have, the bottlenecks presented and ways to alleviate them. NP datasets are plagued by unique challenges—including chemical complexity, sparse bioactivity data, experimental variability, and significant toxicity data gaps—which collectively act as "dust", obscuring reliable predictions. We show how embedding data quality checks during curation and standardization during modelling can improve predictive performance. Additionally, data enrichment by augmentation and hybridization with multi-omics will be a good addition to NP drug discovery. We conclude that giving equal priority to data quality as algorithmic complexity ensures more reliable prediction and translation of AI-driven NP research into tangible therapeutic outcomes.
- 29 March 2026
- Published by University of Nigeria in Advanced Pharmaceutical and Biomedical Letters
- Vol. 2026 (1) , 78-91
Open AccessDusts and De-dusting of Natural Products Datasets: A Critical Review of the Challenges
Machine learning and artificial intelligence have become an established part of natural-products (NP) drug discovery. From bioactivity, hit-identification and lead optimization to toxicity and pharmacokinetic profiling, predictive models have sustained increased momentum. While many review works have focused on the models underlying predictions in NP drug discovery, a detailed understanding of how the quality of the data impacts the predictive process is still lacking. In this narrative review, we undertake the task of unravelling the shortcomings of the current datasets we have, the bottlenecks presented and ways to alleviate them. NP datasets are plagued by unique challenges—including chemical complexity, sparse bioactivity data, experimental variability, and significant toxicity data gaps—which collectively act as "dust", obscuring reliable predictions. We show how embedding data quality checks during curation and standardization during modelling can improve predictive performance. Additionally, data enrichment by augmentation and hybridization with multi-omics will be a good addition to NP drug discovery. We conclude that giving equal priority to data quality as algorithmic complexity ensures more reliable prediction and translation of AI-driven NP research into tangible therapeutic outcomes.
- Open Access
- 23 March 2026
- Published by MDPI AG in Preprints.org
Revisiting BACE-1: How Machine Learning and Molecular Dynamics Unveiled Potential Anti-Alzheimer’s Activity of a Cysteinyl Sulfoxide Derivative
Beta Secretase (BACE-1) is a well-validated target for Alzheimer’s therapies, but have seen attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and MD (250ns) was used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for the BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307±0.109 Å) compared to Verubecestat (1.602±0.159Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (-33.820±4.254) had comparatively lower energy than Verubecestat (-21.090±6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 & Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrate the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.
- 23 March 2026
- Published by MDPI AG in Preprints.org
Open AccessRevisiting BACE-1: How Machine Learning and Molecular Dynamics Unveiled Potential Anti-Alzheimer’s Activity of a Cysteinyl Sulfoxide Derivative
Beta Secretase (BACE-1) is a well-validated target for Alzheimer’s therapies, but have seen attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and MD (250ns) was used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for the BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307±0.109 Å) compared to Verubecestat (1.602±0.159Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (-33.820±4.254) had comparatively lower energy than Verubecestat (-21.090±6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 & Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrate the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.
- Open Access
- 8 April 2025
- Published by Wiley in Health Care Science
- Vol. 4 (2) , 82-93
Are Hospital Pharmacists Ready for Precision Medicine in Nigerian Healthcare? Insights From a Multi‐Center Study
Background: Precision medicine (PM) has taken center stage in healthcare since the completion of the genomic project. Developed countries have gradually integrated PM into mainstream patient management. However, Nigeria still grapples with wide acceptance, key translational research and implementation of PM. This study sought to explore the knowledge and attitude of PM among pharmacists as key stakeholders in the healthcare team.Methods: A cross‐sectional study was conducted in selected tertiary hospitals across the country. A 21‐item semi‐structured questionnaire was administered by hybrid online and physical methods and the results analyzed with Statistical Package for the Social Sciences Version 25. Descriptive statistics were used to summarize the data. A chi‐square test was employed to determine the association of knowledge of PM and the sociodemographic characteristics of the study population.Results: A total of 167 hospital pharmacists participated in the study. A high proportion of the participants are familiar with artificial intelligence (91.75%), Pharmacogenomics (84.5%), and precision medicine (61%). Overall, 38.9% of the pharmacists had a good knowledge while 13.2% had a poor knowledge of PM and associated terms. The level of knowledge did not correlate significantly with gender (X2 = 3.21, p = 0.201), age (X2 = 5, p = 0.27), marital status (X2 = 3.21, p = 0.201), and professional level (X2 = 6.85, p = 0.144). The most important value of precision medicine to hospital pharmacists is the ability to minimize the impact of disease through preventive medicine (49%) while a large portion are pursuing and or actively planning to pursue additional education in precision medicine.Conclusions: There is a highly positive attitude toward the prospect of PM among hospital pharmacists in Nigeria. Education modules in this field are highly recommended as most do not have a holistic knowledge of terms used in PM. Also, more research aimed at translating PM knowledge into clinical practice is recommended.
- 8 April 2025
- Published by Wiley in Health Care Science
- Vol. 4 (2) , 82-93
Open AccessAre Hospital Pharmacists Ready for Precision Medicine in Nigerian Healthcare? Insights From a Multi‐Center Study
Background: Precision medicine (PM) has taken center stage in healthcare since the completion of the genomic project. Developed countries have gradually integrated PM into mainstream patient management. However, Nigeria still grapples with wide acceptance, key translational research and implementation of PM. This study sought to explore the knowledge and attitude of PM among pharmacists as key stakeholders in the healthcare team.Methods: A cross‐sectional study was conducted in selected tertiary hospitals across the country. A 21‐item semi‐structured questionnaire was administered by hybrid online and physical methods and the results analyzed with Statistical Package for the Social Sciences Version 25. Descriptive statistics were used to summarize the data. A chi‐square test was employed to determine the association of knowledge of PM and the sociodemographic characteristics of the study population.Results: A total of 167 hospital pharmacists participated in the study. A high proportion of the participants are familiar with artificial intelligence (91.75%), Pharmacogenomics (84.5%), and precision medicine (61%). Overall, 38.9% of the pharmacists had a good knowledge while 13.2% had a poor knowledge of PM and associated terms. The level of knowledge did not correlate significantly with gender (X2 = 3.21, p = 0.201), age (X2 = 5, p = 0.27), marital status (X2 = 3.21, p = 0.201), and professional level (X2 = 6.85, p = 0.144). The most important value of precision medicine to hospital pharmacists is the ability to minimize the impact of disease through preventive medicine (49%) while a large portion are pursuing and or actively planning to pursue additional education in precision medicine.Conclusions: There is a highly positive attitude toward the prospect of PM among hospital pharmacists in Nigeria. Education modules in this field are highly recommended as most do not have a holistic knowledge of terms used in PM. Also, more research aimed at translating PM knowledge into clinical practice is recommended.